Tang Capital Management’s Puma Biotechnology PBYI Stock Holding History

Tang Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$1.06M	–	161
2025 Q3	$1.06M	Hold	200,000	–	–	0.04%	153
2025 Q2	$686K	Hold	200,000	–	–	0.03%	177
2025 Q1	$592K	Hold	200,000	–	–	0.03%	179
2024 Q4	$610K	Hold	200,000	–	–	0.04%	170
2024 Q3	$510K	Hold	200,000	–	–	0.04%	133
2024 Q2	$652K	Buy	+200,000	New	+$878K	0.07%	102
2020 Q4	–	Sell	-1,246,121	Closed	-$12.6M	–	15
2020 Q3	$12.6M	Sell	1,246,121 -119,255	-9%	-$1.21M	2.27%	11
2020 Q2	$14.2M	Buy	1,365,376 +565,376	+71%	+$5.85M	1.38%	10
2020 Q1	$6.75M	Buy	800,000 +450,600	+129%	+$4.38M	0.95%	13
2019 Q4	$3.06M	Hold	349,400	–	–	0.37%	13
2019 Q3	$3.76M	Hold	349,400	–	–	0.64%	7
2019 Q2	$4.44M	Hold	349,400	–	–	0.6%	7
2019 Q1	$13.6M	Buy	349,400 +102,000	+41%	+$3.12M	2.5%	5
2018 Q4	$5.04M	Buy	+247,400	New	+$7.43M	1.16%	5

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tang Capital Management's PBYI Position: Q4 2025 in Review

Tang Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 200,000 shares — an estimated $1.06M sold.

Tang Capital Management first reported a position in PBYI in Q4 2018 and held it in 14 quarters. The position peaked at $14.2M in Q2 2020. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

Tang Capital Management reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 200,000 Puma Biotechnology shares in Q4 2025, an estimated $1.06M.
Tang Capital Management first reported a position in Puma Biotechnology in Q4 2018 and held it in 14 quarters.
Tang Capital Management's Puma Biotechnology position peaked at $14.2M in Q2 2020.
151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.